http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=402829 A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT - ES Clinical trial Drug clinical trial on-line multicentric Terminated https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003621-28/ES https://reec.aemps.es/reec/estudio/2013-003621-28 http://clinicaltrials.gov/ct2/show/NCT02038933 ES SPAIN International (beyond Europe) II Nivolumab 2023-09-07 00:00:00.0 2013-003621-28 BRISTOL MYERS SQUIBB INTERNATIONAL CORPORATION Sponsor of clinical trial 544 Diffuse large B-cell lymphoma